Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02446600
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-29T15:20:05.609985+00:00
Published At
2021-03-12T00:00:00+00:00
Record Updated At
2026-04-29
Results Posted At
2021-03-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Tumor", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Tumor", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-29"
protocolSection.identificationModule.nctId
"NCT02446600"
protocolSection.identificationModule.officialTitle
"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-03-12"

Study condition terms

  • Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Seromucinous Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.